EnGeneIC Molecular Delivery Pty Ltd
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
7
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for Enhanced loading of intact, bacterially derived vesicles with small molecule compounds (US 10,328,159) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 1 fee due Jun 10, 2027The maintenance fee for Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma (US 10,500,277) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Oct 23, 2027The maintenance fee for Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors (US 11,964,021) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,867,785 | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells In force · From the USPTO record | In force | From the USPTO record | |
| US 8,591,862 | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,169,495 | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells In force · From the USPTO record | In force | From the USPTO record | |
| US 11,357,860 | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells In force · From the USPTO record | In force | From the USPTO record | |
| US 11,147,883 | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells In force · From the USPTO record | In force | From the USPTO record | |
| US 8,691,963 | Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,878,043 | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells In force · From the USPTO record | In force | From the USPTO record | |
| US 10,994,014 | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 11,964,021 | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,731,011 | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 20: 1 lapsed for an unpaid fee · 17 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 4 no status recorded